VYNE Therapeutics
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
-0.43-0.48-0.45-0.29
Price/Sales ratio
72.9372.931.771.34
Earnings per Share (EPS)
$-0.79$-0.7$-0.75$-1.15

Historical Multiples (2015 – 2023)

2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-71.89-23.54-20.33-1.73-2.23-0.80-0.71-0.25-0.84-0.35-1.98
Price/Sales ratio
N/A491.52129.048.39355.489.753.5518.0356.453.18182.62
Price/Book Value ratio
-20.76-11.25-10.360.682.295.461.070.270.260.213.88
Price/Cash Flow ratio
-79.19-144.60-20.93-1.69-2.41-1.49-0.93-0.29-0.94-0.19-2.05
Price/Free Cash Flow ratio
-79.19-142.67-20.91-1.68-2.41-1.49-0.93-0.29-0.94-0.19-2.05
Price/Earnings Growth ratio
N/A-0.11-1.28-0.020.170.150.000.000.01-0.000.16
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
N/A100%100%100%20.99%93.36%77.30%100%100%60.87%40.93%
Operating Profit Margin
N/A-2126.40%-645.85%-512.54%-17210.38%-540.53%-461.07%-7189.72%-6900.47%-514.47%-8861.46%
Pretax Profit Margin
N/A-2087.24%-634.57%-483.50%-16637.24%-1218.62%-500.01%-7113.62%-6573.58%-1382.62%-8560.37%
Net Profit Margin
N/A-2087.24%-634.57%-483.50%-15906.09%-1217.39%-496.97%-7116.35%-6710.37%-898.84%-8194.80%
Effective Tax Rate
N/AN/A0.02%-6.00%4.39%0.10%0.60%-0.03%N/A0.00%2.24%
Return on Assets
-10.50%-33.45%-43.48%-36.76%-89.00%-272.62%-109.37%-83.28%-29.12%-52.94%-70.97%
Return On Equity
28.88%47.78%50.98%-39.45%-102.85%-681.64%-150.77%-108.79%-32.06%-51.52%-77.19%
Return on Capital Employed
-10.68%-37.56%-50.11%-41.82%-111.28%-156.97%-139.87%-109.17%-32.45%-35.47%-76.55%
Liquidity Ratios
Current Ratio
N/AN/AN/AN/AN/A4.06N/AN/AN/A6.442.03
Quick Ratio
56.998.088.5514.617.213.723.034.0812.735.996.60
Cash ratio
56.891.031.305.182.882.682.293.304.065.194.03
Days of Sales Outstanding
N/AN/A62.61N/AN/A275.04187.583.82KN/A722.73361.36
Days of Inventory outstanding
N/AN/AN/AN/A1.41K1.94K794.86N/AN/AN/A1.67K
Operating Cycle
N/AN/AN/AN/A1.41K2.21K982.45N/AN/A178.201.81K
Days of Payables Outstanding
N/AN/AN/AN/A3.93K1.25K709.72N/AN/A1.01K2.59K
Cash Conversion Cycle
N/AN/AN/AN/A-2.51K963.08272.72N/AN/A-297.08-1.40K
Debt Ratios
Debt Ratio
N/AN/AN/AN/AN/A0.360.00N/A0.000.140.18
Debt Equity Ratio
N/AN/AN/AN/AN/A0.900.00N/A0.000.170.45
Long-term Debt to Capitalization
N/AN/AN/AN/AN/A0.46N/AN/AN/AN/A0.23
Total Debt to Capitalization
N/AN/AN/AN/AN/A0.470.00N/A0.00N/A0.23
Interest Coverage Ratio
N/AN/AN/AN/AN/A-25.84N/AN/AN/AN/A-12.92
Cash Flow to Debt Ratio
N/AN/AN/AN/AN/A-4.04-161.51N/A-220.35N/AN/A
Company Equity Multiplier
-2.75-1.42-1.171.071.152.501.371.301.101.171.11
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
N/A-3.39-6.16-4.95-146.95-6.52-3.82-61.21-59.76-16.40-81.67
Free Cash Flow / Operating Cash Flow Ratio
11.011.001.001.001.0011111.00
Cash Flow Coverage Ratio
N/AN/AN/AN/AN/A-4.04-161.51N/A-220.35N/AN/A
Short Term Coverage Ratio
N/AN/AN/AN/AN/A-181.08-161.51N/A-220.35N/AN/A
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A